Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a significant milestone in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital. The company announced that patient enrollment has hit the halfway point, and preliminary imaging data have shown encouraging signals in acute MS lesions, along with potential sensitivity to gray matter lesions.
The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, the process of myelin degradation that underlies MS. This technique could provide a more direct way to measure disease activity and treatment response. The company believes this imaging approach could enhance the development of MS therapies, including its own investigational candidate Lucid-MS.
Quantum BioPharma recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in March 2026 for a Phase 2 trial of Lucid-MS. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. The positive preliminary imaging results may support the advancement of Lucid-MS into clinical trials.
The study's midpoint enrollment milestone is a critical step in validating the imaging technique, which could become a valuable tool for assessing demyelination in MS patients. If successful, this technique might also be used to monitor the efficacy of other MS therapies, potentially speeding up drug development and improving patient outcomes.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is leading the development of Lucid-MS. The company also has a stake in Unbuzzd Wellness Inc., which markets an over-the-counter product called UNBUZZD™, and retains royalty rights on sales.
For more information on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM. To view the full press release, go to https://ibn.fm/4IZ0y.
